Compositions and their uses directed to huntingtin
First Claim
1. An antisense oligonucleotide 12 to 35 nucleotides in length comprising at least 12 consecutive nucleotides having at least 90% complementarity to nucleotides 4856-4894 of SEQ ID NO:
- 4, wherein the antisense oligonucleotide has a gap segment positioned between 5′ and
3′
wing segments.
1 Assignment
0 Petitions
Accused Products
Abstract
Disclosed herein are compounds, compositions and methods for modulating the expression of huntingtin in a cell, tissue or animal. Further provided are methods of slowing or preventing Huntington'"'"'s Disease (HD) progression using an antisense compound targeted to huntingtin. Additionally provided are methods of delaying or preventing the onset of Huntington'"'"'s Disease (HD) in an individual susceptible to Huntington'"'"'s Disease (HD). Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders.
50 Citations
20 Claims
-
1. An antisense oligonucleotide 12 to 35 nucleotides in length comprising at least 12 consecutive nucleotides having at least 90% complementarity to nucleotides 4856-4894 of SEQ ID NO:
- 4, wherein the antisense oligonucleotide has a gap segment positioned between 5′ and
3′
wing segments. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)
- 4, wherein the antisense oligonucleotide has a gap segment positioned between 5′ and
Specification